Thursday, November 12, 2026

Corporate Fraud Losses Hit $41B Globally as 58% of Payment Teams Skip Verification Under Time Pressure

58% of accounts payable professionals worldwide skip fraud verification steps due to time constraints, driving $41 billion in annual corporate losses. Manual verification requires 8-12 minutes per invoice, prompting teams processing 15-30 daily invoices to cut corners. AI-automated systems complete 100% of checks in 2-4 minutes, achieving 94% fraud detection versus 67% for manual processes.

ViaNews Editorial Team

February 28, 2026

Corporate Fraud Losses Hit $41B Globally as 58% of Payment Teams Skip Verification Under Time Pressure
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.

58% of accounts payable professionals globally admit to skipping verification steps at least occasionally due to time constraints, according to PYMNTS research. This verification failure translates to $41 billion in annual corporate fraud losses across businesses worldwide, with U.S. companies bearing the largest share.

Time pressure drives the problem across markets. AP teams face 15-30 invoice verifications daily per processor. Manual checks require 8-12 minutes per invoice for vendor validation, duplicate detection, and approval workflows. Under deadline pressure, verification steps get cut.

AI-automated verification eliminates the speed-accuracy tradeoff. Systems process invoices in 2-4 minutes while completing 100% of fraud checks. Pelican Canada Inc., operating across North American markets for 25 years, reports zero verification skips across clients processing 500,000+ monthly transactions.

"Production-ready AI strategy relies on data quality," says Peter Cavicchia, payment processing expert. Clean vendor databases and transaction histories train AI models to flag anomalies humans miss under time pressure—a challenge consistent across regulatory environments from North America to Europe and Asia-Pacific.

The verification gap creates three systemic risks globally. Duplicate payments slip through when processors skip cross-reference checks. Fraudulent vendor account changes bypass approval workflows. Invoice manipulation goes undetected without amount verification against purchase orders.

Manual AP departments show fraud detection rates of 67% compared to 94% for AI-assisted teams, industry benchmarks indicate. The 27-point gap costs mid-market companies $180,000-$320,000 annually in undetected fraud—figures that scale proportionally in high-cost markets like Western Europe and Japan.

Processing speed compounds with scale. Companies handling 10,000+ monthly invoices cannot maintain manual verification coverage. AI systems scale linearly—processing 100,000 invoices requires the same per-transaction time as 1,000.

Compliance teams worldwide face pressure to eliminate verification shortcuts. Regulations from Sarbanes-Oxley in the U.S. to GDPR requirements in Europe mandate consistent AP processes. The 58% skip rate creates audit findings and control weakness disclosures across jurisdictions.

Implementation requires data preparation. AI models need 6-12 months of clean transaction history for training. Companies with poor data governance delay AI adoption 8-14 months. AP fraud increased 23% year-over-year in 2025 globally, while AI processing costs drop below $2 per transaction.


Sources:
1 Yahoo Finance, "Ocham's Razor Capital Limited Announces Reverse Takeover Transaction With Pelican Canada Inc. and Br" (February 23, 2026)
2 Yahoo Finance, "Pure Storage Becomes Everpure; Announces Intent to Acquire 1touch" (February 23, 2026)

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Biotech Catalyst Wave: Late-2026 Clinical Readouts, PDUFA Dates and Capital Restructuring
A dense cluster of Q4 2026 to Q1 2027 clinical and regulatory catalysts spans hepatitis delta (Vir's ECLIPSE/SOLSTICE), hypertension and sleep apnea (Mineralys' lorundrostat, PDUFA 2026-12-22), severe hypertriglyceridemia (plozasiran), oncology (ivonescimab BLA, PDUFA 2026-11-14) and gene therapy (Krystal). Positive data flow from AASLD and AHA presentations is offset by cost-cutting guidance, milestones slipping into 2027, and a delisting process that signals capital-market stress for some issuers. Near-term value hinges on binary FDA decisions and Phase 3 topline readouts in Q1 2027.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,565 source documents archived
Query this data → isubstrate.com